EICHORCondition: Sickle Cell Disease · Sponsor: Sangamo Therapeutics
This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| UCSF Benioff Children's Hospital | Oakland, California, United States | — |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | — |
| Investigational Site Number 101 | Bethesda, Maryland, United States | — |
| Karmanos Cancer Institute | Detroit, Michigan, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03653247